Incyte Genomics Inc (INCY)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.50 (-0.76%)Past Day

About

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Key Insights

  • Share Price

    $64.98

  • Market Cap

    $12.52 Billion

  • Total Outstanding Shares

    192.60 Million Shares

  • Total Employees

    2,524

  • Dividend

    No dividend

  • IPO Date

    November 3, 1993

  • SIC Description

    Services-commercial Physical & Biological Research

  • Homepage

    https://www.incyte.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2023 to June 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-61.19 Million
Net Cash Flow, Continuing$-2.14 Billion
Net Cash Flow From Investing Activities$-30.98 Million
Net Cash Flow From Operating Activities, Continuing$-61.19 Million
Net Cash Flow From Financing Activities$-2.05 Billion
Net Cash Flow From Investing Activities, Continuing$-30.98 Million
Exchange Gains/Losses$-5.25 Million
Net Cash Flow From Financing Activities, Continuing$-2.05 Billion
Net Cash Flow$-2.14 Billion

Income Statement

July 1, 2023 to June 30, 2024
MetricValue
Basic Earnings Per Share$0.42
Diluted Earnings Per Share$0.41
Costs And Expenses$3.84 Billion
Net Income/Loss Available To Common Stockholders, Basic$97.30 Million
Benefits Costs and Expenses$3.51 Billion
Revenues$3.86 Billion
Cost Of Revenue$267.43 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Selling, General, and Administrative Expenses$1.17 Billion
Gross Profit$3.59 Billion
Net Income/Loss Attributable To Parent$97.30 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations After Tax$97.30 Million
Income Tax Expense/Benefit$253.84 Million
Operating Expenses$3.57 Billion
Income/Loss From Continuing Operations Before Tax$351.14 Million
Preferred Stock Dividends And Other Adjustments$0.00
Operating Income/Loss$15.74 Million
Research and Development$2.39 Billion
Basic Average Shares$666.94 Million
Net Income/Loss$97.30 Million
Diluted Average Shares$671.73 Million

Balance Sheet

July 1, 2023 to June 30, 2024
MetricValue
Equity Attributable To Parent$3.00 Billion
Liabilities$1.66 Billion
Other Current Assets$2.47 Billion
Assets$4.66 Billion
Other Non-current Assets$1.33 Billion
Noncurrent Assets$2.09 Billion
Fixed Assets$762.01 Million
Wages$113.54 Million
Current Assets$2.57 Billion
Noncurrent Liabilities$327.69 Million
Accounts Payable$148.17 Million
Liabilities And Equity$4.66 Billion
Equity$3.00 Billion
Other Current Liabilities$1.08 Billion
Current Liabilities$1.34 Billion
Equity Attributable To Noncontrolling Interest$0.00
Inventory$100.70 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
News ArticlesAbout UsPrivacy Policy & Cookies Information

ⓒ2024 Financhle. All Rights Reserved.